Cyclacel Reports Phase 2 Survival Data With Sapacitabine in Myelodysplastic Syndromes at 2010 ASH Annual Meeting

BERKELEY HEIGHTS, N.J., Dec. 4, 2010 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel”) announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at [...] http://bit.ly/gLKnn9